文献速递中医内科中药与中成药合理使用中医骨伤

达鲁替醇经JAK-STAT3通路减轻胶原诱导性关节炎小鼠炎症与软骨降解

An integrated network pharmacology approach reveals that Darutigenol reduces inflammation and cartilage degradation in a mouse collagen-induced arthritis model by inhibiting the JAK-STAT3 pathway.
PubMed 文献 · J Ethnopharmacol · 2023-05-07

本研究探讨中药豨莶草活性成分达鲁替醇(DL)治疗类风湿关节炎(RA)的作用与机制。采用网络药理学与分子对接筛选靶点,并在牛II型胶原诱导的DBA/1小鼠RA模型中灌胃给药,评估关节炎指数、踝关节病理及ELISA/WB指标。结果显示DL可减轻关节红肿、降低关节炎指数及IL-6水平,并下调JAK1、JAK3、MMP2、MMP9和p-STAT3蛋白,提示其经IL-6/JAK1,3/STAT3轴发挥抗RA作用。

要点

  • DL可减轻CIA小鼠踝关节红肿、降低关节炎指数及血清与骨髓上清IL-6水平。
  • DL改善滑膜炎、软骨降解与骨侵蚀,并下调关节JAK1、JAK3、MMP2、MMP9及p-STAT3。
  • 网络药理学筛选出DL的6个关键靶点,分子对接显示其与靶蛋白结合良好。

核心结论

  • DL在CIA小鼠模型中具有显著抗炎 efficacy,可减少软骨降解与骨侵蚀。
  • DL的抗RA作用可能通过抑制IL-6/JAK1,3/STAT3轴并下调MMP2、MMP9实现。
  • DL可能在小鼠RA模型中发挥治疗作用。

研究设计与样本

  • 研究采用网络药理学与分子对接筛选并验证DL治疗RA的候选靶点。
  • 采用牛II型胶原诱导的DBA/1小鼠类风湿关节炎模型,灌胃给予DL后计算临床关节炎指数。
  • 取踝关节切片染色观察病理变化,并用ELISA与Western blotting阐明机制。

主要发现

  • DL治疗组踝关节红肿与肿胀显著轻于CIA组,关节炎指数评分更低。
  • DL治疗组血清与骨髓上清IL-6水平显著低于CIA组。
  • DL治疗组踝关节表面更完整,滑膜炎、软骨降解与骨侵蚀更少。
  • DL治疗显著下调关节内JAK1、JAK3、MMP2、MMP9与p-STAT3蛋白。
  • 网络药理学筛选出DL的6个关键靶点,分子对接显示其与蛋白靶点对接良好。

临床怎么用

  • 豨莶草作为祛风湿、利关节、解毒中药,其活性成分DL的抗RA机制获得实验支持。
  • DL可能通过IL-6/JAK1,3/STAT3轴及MMP2/MMP9通路减轻RA关节炎症与结构损伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Darutigenol (DL) is a natural active product derived from the Chinese herbal medicine Sigesbeckia glabrescens (Makino) Makino. It is administered as a traditional Chinese medicine (TCM) to dispel rheumatism, benefit the joints, and detoxify. However, its potential mechanism in the treatment of rheumatoid arthritis (RA) remains unknown. AIMS OF THE STUDY: The objectives of this research were to determine the effects and elucidate the modes of action of DL on RA-related joint inflammation. MATERIALS AND METHODS: Network pharmacology and molecular docking were used to screen and validate candidate DL targets for RA treatment, respectively. A DBA/1 mouse rheumatoid arthritis model was induced with bovine type II collagen. Intragastric DL administration was followed by the calculation of the clinical arthritis index. A section of the ankle joint was excised and stained and the pathological changes in it were observed. Enzyme-linked immunosorbent assays (ELISA) and western blotting (WB) were used to clarify the mechanisms of DL in RA treatment. RESULTS: DL effectively attenuated the inflammation, mitigated the articular cartilage degradation, and bone erosion, and alleviated the inflammatory joints associated with RA. Network pharmacology screened six key targets of DL while molecular docking revealed that it docked well with its protein targets. The DL treatment group presented with significantly less ankle joint redness and swelling, a lower arthritis index scores and serum and bone marrow supernatant IL-6 levels, more complete ankle joint surfaces, and less synovial inflammation, cartilage degradation, and bone erosion than the collagen-induced arthritis (CIA) group. The DL treatment also substantially downregulated the Janus kinase (JAK)1, JAK3, matrix metalloproteinase (MMP)2, MMP9, and phospho-signal transducer and activator of transcription (p-STAT)3 proteins in the joints. CONCLUSIONS: To the best of our knowledge, the present work was the first to demonstrate that DL has significant anti-inflammatory efficacy and reduces cartilage degradation and bone erosion. It also demonstrated that the anti-RA effect of DL may be explained by its ability to inhibit joint inflammation and reduce articular cartilage degradation through the interleukin (IL)-6/JAK1,3/STAT3 axis and downregulate MMP2 and MMP9. Hence, DL might play a therapeutic role in a mouse RA model.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Yan H, Zhao L, et al. An integrated network pharmacology approach reveals that Darutigenol reduces inflammation and cartilage degradation in a mouse collagen-induced arthritis model by inhibiting the JAK-STAT3 pathway. J Ethnopharmacol. 2023. PMID: 37160212. doi:10.1016/j.jep.2023.116574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。